NASDAQ:RAIN Rain Oncology (RAIN) Stock Price, News & Analysis → The only AI company to buy (From Porter & Company) (Ad) Free RAIN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.21▼$1.2150-Day Range$1.20▼$1.2452-Week Range$0.82▼$11.32VolumeN/AAverage Volume550,818 shsMarket Capitalization$44.02 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrends Get Rain Oncology alerts: Email Address Ad Weiss RatingsOn June 10, Nvidia makes its next big moveA small handful of companies are working with Nvidia to help ensure that this pivot is a massive success. We call them Nvidia’s “Silent Partners.”Click here to find out who they are. About Rain Oncology Stock (NASDAQ:RAIN)As of January 26, 2024, operates as a subsidiary of Pathos AI, Inc.Read More Ad Porter & CompanyThe only AI company to buyThe AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. RAIN Stock News HeadlinesMay 29 at 6:31 PM | msn.comBring the Family to run4DAD: Run, Walk, Trot or Cheer the RunnersMay 28, 2024 | msn.comAsk A Doctor: What Are The Benefits Of Rain Sounds For Relaxation And Sleep?May 26, 2024 | uk.news.yahoo.comThousands of Edinburgh marathon runners remain upbeat despite torrential rainMay 25, 2024 | msn.comManitoba motorcyclists brave rain to raise funds, 'critical' awareness for prostate cancerMay 23, 2024 | msn.comBritain's King Charles formally approves proroguing of UK parliament ahead of electionMay 22, 2024 | uk.news.yahoo.comPrince William and his cousins rally round to step in for King Charles as he continues cancer treatmentMay 21, 2024 | msn.comSunshine comes to abrupt end as yellow warning for rain in place for West LothianMay 18, 2024 | yahoo.comRain doesn’t dampen effort to fight cancer in LebanonMay 18, 2024 | yahoo.comLakeside raises money to fight cancerMay 16, 2024 | yahoo.comCancer Survivors Are Sharing The Symptom That Finally Made Them Go To The DoctorMay 13, 2024 | finance.yahoo.comAdvertising Agency PPK Aims to Fight Pediatric Cancer with Children's Book Raising Funds for the National Pediatric Cancer FoundationMay 12, 2024 | msn.comWhat to know ahead of this weekend's Avera Race Against CancerMay 11, 2024 | msn.comTrumbull County Relay for Life raises money for American Cancer SocietyMay 7, 2024 | msn.comKing Charles III is 'very good' amid cancer treatment, won't see Harry during prince's U.K. visitMay 7, 2024 | sports.yahoo.comRain forces changes to YAIAA baseball and softball tournament datesMay 6, 2024 | msn.comScott Dunlap declared PGA Tour Champions winner after final round washed outMay 6, 2024 | washingtonpost.comDunlap declared PGA Tour Champions winner after rain washes out final roundMay 5, 2024 | yahoo.com‘Rick’s Fun Run’ helps teacher battling cancerMay 5, 2024 | msn.comThousands brave rain for 27th annual Race for Hope DCMay 3, 2024 | msn.comBreast cancer survivors beat the rain during Kentucky Oaks Day Survivors ParadeMay 3, 2024 | msn.comLIVE UPDATES: Clouds, rain don't dampen spirits on Oaks Day at Churchill DownsMay 2, 2024 | msn.comWeather Impact Day: Heavy rain, possible thunderstorms on SaturdayMay 2, 2024 | msn.comJohnson & Johnson wants to pay $6.5B to settle talcum-powder lawsuits over cancer claimsMay 2, 2024 | yahoo.comWatch David Gilmour wring every ounce of emotion from the guitar solo on Prince's Purple Rain – with Tom JonesMay 1, 2024 | msn.comTalking to your kids about child abuseSee More Headlines Receive RAIN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rain Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today6/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:RAIN CUSIPN/A CIK1724979 Webwww.rainthera.com Phone510-953-5559FaxN/AEmployees63Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-75,720,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-82.96% Return on Assets-68.31% Debt Debt-to-Equity RatioN/A Current Ratio5.58 Quick Ratio5.58 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.11 per share Price / Book0.39Miscellaneous Outstanding Shares36,380,000Free Float30,047,000Market Cap$44.02 million OptionableOptionable Beta0.27 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Avanish Vellanki M.B.A. (Age 49)Co-Founder, CEO & Chairman Comp: $959.75kDr. Robert C. Doebele M.D. (Age 53)Ph.D., Co-Founder, Chairman of Scientific Advisory Board, President & CSO and Chief Medical Officer Comp: $700.56kMs. Josephine Bruce (Age 45)Principal Financial & Accounting officer Ms. Theresa O'Connell M.S.Director of Corporate Development & OperationsMr. Erik Atkisson (Age 52)General Counsel & Chief Compliance Officer Ms. Charmi TurnerVice President of People & CultureMs. Vijaya Tirunagaru Ph.D.Senior VP & Head of ResearchDr. Nora Ku M.D.MD & VP of Clinical DevelopmentMore ExecutivesKey CompetitorsBiora TherapeuticsNASDAQ:BIORPMV PharmaceuticalsNASDAQ:PMVPDiaMedica TherapeuticsNASDAQ:DMACMural OncologyNASDAQ:MURALianBioNASDAQ:LIANView All CompetitorsInsidersKevin C TangSold 40,132 sharesTotal: $48,559.72 ($1.21/share)Kevin C TangSold 109,435 sharesTotal: $131,322.00 ($1.20/share)Kevin C TangBought 131,631 shares on 10/13/2023Total: $130,314.69 ($0.99/share)Kevin C TangBought 74,812 shares on 10/11/2023Total: $72,567.64 ($0.97/share)Kevin C TangBought 333,325 shares on 6/1/2023Total: $369,990.75 ($1.11/share)View All Insider Transactions RAIN Stock Analysis - Frequently Asked Questions Should I buy or sell Rain Oncology stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rain Oncology in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" RAIN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RAIN, but not buy additional shares or sell existing shares. View RAIN analyst ratings or view top-rated stocks. How were Rain Oncology's earnings last quarter? Rain Oncology Inc. (NASDAQ:RAIN) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.70) earnings per share for the quarter, missing analysts' consensus estimates of ($0.64) by $0.06. When did Rain Oncology IPO? Rain Oncology (RAIN) raised $126 million in an initial public offering on Friday, April 23rd 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. Goldman Sachs, Citigroup, Piper Sandler and Guggenheim Securities served as the underwriters for the IPO. This page (NASDAQ:RAIN) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking: One AI startup's revenue could surge 4,735%Manward PressMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rain Oncology Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.